Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 8/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 3/20 | 0.32 |
| ▸ | ADH1C | P00326 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002550 | 0.98 | PRMT1 (0.42) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL12478238 | 0.98 | PRMT1 (0.46) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL12478430 | 0.91 | — | — | |
| SCHEMBL13532565 | 0.85 | SIGMAR1 (0.46) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL13744550 | 0.83 | CARM1 (0.41) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL14303965 | 0.81 | PRMT3 (0.39) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL20079259 | 0.81 | PIK3CD (0.50) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL8851169 | 0.81 | PRMT3 (0.39) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL8851165 | 0.81 | PRMT3 (0.39) | PRMT1CARM1PRMT6PRMT3PRMT8 | |
| SCHEMBL23407883 | 0.79 | KDM4E (0.39) | PRMT1CARM1PRMT6PRMT3PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678349-B1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-2678349-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012115256-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | WO | disclosed |
| WO-2004056784-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | PRMT1 1663/4885CARM1 2765/4885PRMT6 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.